Calendario›REGN›REGN9933 · ROXI-CATH

REGN9933 · ROXI-CATH

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

Ensayo de REGENERON PHARMACEUTICALS, INC. en Venous Thromboembolism (del registro, en inglés).

Fase

Fase 2

Estado

Completado

Participantes

195

previstos

Centros

23

Fin del objetivo primario

mar 2026

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en sep 2024.

Qué mide

Incidence of confirmed VTE per central reading center (CRC) review (Through Day 14) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related disease after catheter placement. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06299111), actualizada en abr 2026.